Abstract: A method for reducing the rise in intracranial pressure accompanying head trauma includes the steps of significantly reducing the mean trauma induced increase in blood brain barrier permeability by administering an effective dose of an analog of amino acids 4-9 of adrenocorticotropin hormone, thereby significantly reducing the peak rise in intracranial pressure which normally acompanies the trauma.

Abstract: Pharmaceutical compositions containing Virginiamycin M.sub.1 having the Formula: ##STR1## and Virginiamycin M.sub.1 analogs having the Formulae I-IV: ##STR2## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a cotinine compound.

Abstract: A method of relieving pain comprises administering, to the subject suffering from the pain, a pharmaceutically effective amount of glucagon and a spasmogenic analgesic. A ratio of 0.1-10 parts of glucagon per 10 parts of analgesic is administered.Furthermore, the use of glucagon for the preparation of a pharmaceutical preparation for treating pain is disclosed.

Abstract: A class of Glycine B partial agonists is described for use for treatment of psychosis. Preferred Glycine B partial agonists include amino-isoxazolidone compounds such as D-cycloserine and its prodrugs.

Abstract: The invention provides ibuprofen and ibuprofen containing pharmaceutical preparations stabilized against thermal degradation by the presence of a phenolic type antioxidant.

Abstract: Pharmaceutical compositions containing Triazolobenzodiazepines of the formula: ##STR1## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

Abstract: There is disclosed, in one aspect, chlorous acid generating compositions useful for disinfecting substrates. The compositions comprise aqueous solutions containing a suitable amount of a protic acid, such as citric or malic acid, and a suitable amount of a metal chlorite, such as sodium chlorite. The chlorite ion concentration which is in the form of chlorous acid in the composition is no more than about 15 percent by weight of the total amount of chlorite ion concentration. In a preferred embodiment, the composition also contains a vicinal dihydroxy or polyhydroxy compound. In another preferred embodiment, the composition contains at least a 10-fold molar excess of a water soluble chloride ion compared to the total concentration of chlorite ion. In another aspect, there is disclosed a process for disinfecting substrates. This process comprises applying the compositions described above to a substrate. In yet another aspect, there is disclosed a process for preparing the compositions described above.

Abstract: Oral compositoins containing a gastroprotective amount of zirconium-aluminum glycinate, aluminum chlorohydrate or a mixture thereof are disclosed. A method for protecting the gastric mucosa against injury caused by a gastric irritant such as NSAIDs is also disclosed.

Abstract: The invention relates to a method of treating alcoholism, sleep disorders or behavioral symptoms of Alzheimer's disease which comprises administration of bridged 2-(4-arylpiperazin-1-ylalkyl)-hexahydroisoindol-1,3-dione derivatives to a warm-blooded animal in need thereof.

Abstract: Pharmaceutically elegant oral compositions of non-steroidal anti-inflammatory drugs or their salts are prepared by adding selected dispersing agents such as a polyvinylpyrrolidone, hydroxypropyl-methylcellulose or hydroxypropylcellulose to the NSAIDs in a medium of polyol-glycol-alcohol. The compositions offer the formation of finely dispersed active ingredients upon dispersion in gastric juice.

Abstract: The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for prevention, treatment, inhibition or reversal of renal dysfunction or disease, especially renal failure.

Abstract: A pharmaceutical composition is used to treat and prevent a diabetes-dependent type of autoimmune diseases, said pharmaceutical composition comprising a therapeutically effective amount of 3-oxygermylpropionic acid represented by the following formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 CO.sub.2 H].sub.nwherein n stands for an integer of 1 or more, optionally with an activating carrier.

Abstract: Persons suffering from negative symptoms of schizophrenia can be successfully treated using a histamine H.sub.2 -antagonist which crosses the blood-brain barrier so as to interact with histamine-H.sub.2 receptors in the brain. A preferred H.sub.2 -antagonist is famotidine. The H.sub.2 -antagonist may be used alone in patients who are relatively free of positive symptoms or it may be used in combination with known neuroleptics. A pharmaceutical composition containing both an H.sub.2 -antagonist and a neuroleptic is part of the present invention.

Abstract: Compounds of formula I ##STR1## wherein X and Y are each independently of the other thio or sulfynyl, R.sub.1 is lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2--yn-1-yl, or lower alkyl that is substituted in the 2,3-position by radicals that can be eliminated to form a double bond, R.sub.2 is hydrogen and R.sub.3 is unsubstituted methyl or methyl substituted by a radical that can be eliminated together with hydrogen Rhd 2 to form a double bond, or R.sub.2 and R.sub.3 are each hydrogen or lower alkyl or together are methylene, R.sub.4 is free or protected hydroxy, or hydrogen, and R.sub.5 is hydrogen, lower alkyl, lower alk-2-en-1-yl, lower alk-2-yn-1-yl, or lower alkyl that is substituted in the 2,3-position by radicals that can be eliminated to form a double bond, and their pharmaceutically acceptable salts may be used in a novel manner for the treatment of disorders of the rheumatoid type.

Abstract: Parenterally injectable compositions for controlling parasites, which compositions contain from 0.1 to 10% of a benzoylurea as active ingredient, from 0.1 to 60% of a 1-substituted azacycloalkan-2-one, from 2 to 90% of a physiologically tolerable surfactant or mixture of surfactants and, if appropriate, as stabilizing component, from 0.05 to 15% of an acid or a buffer mixture and add 100% of a physiologically tolerable hydrophilic solvent or mixture of solvents or a mixture of physiologically tolerable hydrophilic and lipophilic solvents.

Abstract: Pharmaceutical compositions containing 6-membered heterocyclic rings are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

Abstract: A method of delivering ephedrine base in vapor form from a composition containing the ephedrine base and an alkyl salicylate. Methyl salicylate is the preferred alkyl salicylate. Optional ingredients in the composition include aromatic compounds such as menthol, camphor, and various other essential oils. The method is particularly useful in the treatment of nasal congestion and bronchial asthma. A preferred means of delivering the ephedrine base in vapor form in the treatment of nasal congestion and bronchial asthma is a vapor inhaler.

Abstract: There are disclosed pharmaceutical preparations and methods for the use thereof which have a cardioprotective action useful in coronary insufficiency, in the prevention of the constitution of an infarction or of sudden death. It consists in the utilization of amiodarone, a nitrate derivative and a beta-blocker.

Abstract: Gallium compounds are utilized to treat or inhibit arthritis.